Acronym:
ACTRN/NCT /ethics:
NCT02576574
Scientific title:
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer.
Summary of trial and patient characteristics
| Cancer Type | Lung & mesothelioma | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase III | Tumour Stream | Non-Small Cell Lung Cancer |
| Age Range | 18 years and older | Cancer Stage | |
| Sex | Both | Anticipated Start Date | 2015-10-29 |
| Molecular Target | Anticipated End Date | 2024-07-26 | |
| Cancer Type | Lung & mesothelioma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Non-Small Cell Lung Cancer |
| Cancer Stage | |
| Anticipated Start Date | 2015-10-29 |
| Anticipated End Date | 2024-07-26 |
Trial Summary
The purpose of this study is to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumors
Lay Summary
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer.
Sponsor / Cooperative group
EMD Serono Research & Development Institute, Inc.
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Queen Elizabeth Hospital | Sue Yeend | Sue.Yeend@sa.gov.au | 08 8222 6148 | R Roberts-Thomson | Recruitment on Hold |